Academic Journal
Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
| العنوان: | Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China |
|---|---|
| المؤلفون: | Sang, Haiqiang, Wan, Yiming, Ma, Zhenzhou, Zhang, Shengye, Zhao, Qiuping |
| المصدر: | Frontiers in Cardiovascular Medicine ; volume 9 ; ISSN 2297-055X |
| بيانات النشر: | Frontiers Media SA |
| سنة النشر: | 2022 |
| المجموعة: | Frontiers (Publisher - via CrossRef) |
| الوصف: | Aim To determine the pharmacoeconomics of empagliflozin for the treatment of heart failure (HF) with reduced ejection fraction in China and to provide evidence-based reference for clinical rational drug selection and medical decision-making. Research design and methods We used the Markov model to evaluate the cost-effectiveness of empagliflozin for the treatment of HF with reduced ejection fraction (HFrEF). We evaluated the cost-effectiveness of the standard treatment in addition to empagliflozin (empagliflozin group) vs. the cost-effectiveness of the standard treatment alone (standard treatment group). Results We found that each additional quality-adjusted life year (QALY) in the empagliflozin group costed $3,842.20 more, which was less than China’s gross domestic product (GDP) per capita in 2021 ($11,981). The steady-state mortality in the two groups was the key factor affecting the incremental cost-effectiveness ratio (ICER). Probabilistic sensitivity analysis revealed that when the willingness-to-pay (WTP) threshold was one time the GDP per capita in 2021 ($11,981) and three times the GDP per capita in 2021 ($35,943), the probability of the empagliflozin group being cost-effective was 85.8 and 91.6%, respectively. Conclusion Compared with the standard treatment alone, the addition of empagliflozin to the standard treatment was more cost-effective for the treatment of HFrEF in China. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| DOI: | 10.3389/fcvm.2022.1022020 |
| DOI: | 10.3389/fcvm.2022.1022020/full |
| الاتاحة: | http://dx.doi.org/10.3389/fcvm.2022.1022020 https://www.frontiersin.org/articles/10.3389/fcvm.2022.1022020/full |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.19D831A4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3389/fcvm.2022.1022020 |
|---|